FRONTIER1 multiple ascending dose extension: a safety, tolerability, pharmacokinetics, and pharmacodynamics study of Mim8 in people with hemophilia A
Mim8 was well tolerated, with no safety concerns nor anti-Mim8 antibodies during the FRONTIER1 MAD extension, supporting phase 3 development of Mim8 once weekly and once every 4 weeks.
Authors
- Francisco José López‐Jaime (ORCID: https://orcid.org/0000-0003-2407-3901)
- Peter Nørkjær Laursen
- Lidia Gil (ORCID: https://orcid.org/0000-0003-0700-3637)
- Jerzy Windyga (ORCID: https://orcid.org/0000-0001-7877-4784)
- Pratima Chowdary (ORCID: https://orcid.org/0000-0002-6690-8586)
- Steven R. Lentz (ORCID: https://orcid.org/0000-0002-8885-4718)
- Johnny Ndoni Mahlangu (ORCID: https://orcid.org/0000-0001-5781-7669)
- Wan Hui Ong Clausen
Institutions
- Poznan University of Medical Sciences (PL)
- University of Iowa (US)
- Novo Nordisk (Denmark) (DK)
- Instytut Hematologii i Transfuzjologi (PL)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.rpth.2025.103207
- Citations
- 1
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77